GGHC
TCRT icon

Gilder Gagnon Howe & Co’s Alaunos Therapeutics TCRT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-70
Closed -$95K – 263
2015
Q3 		$95K Sell
70
-163
-70% -$269K ﹤0.01% 234
2015
Q2 		$420K Buy
+233
New +$362K 0.01% 235

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gilder Gagnon Howe & Co's TCRT Position: Q4 2015 in Review

Gilder Gagnon Howe & Co sold out of Alaunos Therapeutics (TCRT) in Q4 2015, closing a stake of 70 shares — an estimated $95K sold.

Gilder Gagnon Howe & Co first reported a position in TCRT in Q2 2015 and held it in 2 quarters. The position peaked at $420K in Q2 2015. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2015.

  • Gilder Gagnon Howe & Co reported no remaining Alaunos Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 70 Alaunos Therapeutics shares in Q4 2015, an estimated $95K.
  • Gilder Gagnon Howe & Co first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Alaunos Therapeutics position peaked at $420K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2015, filed 4 Feb 2016.